Skip to main content
Signal8
Launch Terminal

MACROGENICS INC (MGNX)

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company’s product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

MacroGenics, Inc. logo

MacroGenics, Inc.

NASDAQ:MGNXHealthcare
+0.84%$2.40
AH$2.40+0.00%vs close
Mkt Cap$153M
Float62.12M
O/S63.75M
Vol
$ Vol
RVOL
Inst Own75.9%
SI8.2%
Earnings
Dilution
MacroGenics, Inc. logoNASDAQ:MGNX$2.40+0.84%
Upcoming Catalysts
  • lorigerlimabREADOUT
    Cash runway at this date: 13mo
    First half of 2027~34w8-K
  • MGC026READOUT
    Cash runway at this date: 13mo
    Mid-2027~34w8-K
  • lorigerlimabREADOUT
    Cash runway at this date: 21mo
    Oct 26, 20267d ago8-K
Phase Distribution
42 lead-sponsored trials·5 active·22 completed
Phase 122
Phase 1/25
Phase 27
Phase 2/33
Phase 32
Not applicable3
(12 more as collaborator)

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Terminated

    Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

    Teplizumab Herold Regimen, Placebo

    Type 1 Diabetes Mellitus

    Enrollment
    254
    Start
    Sep 2009
    Primary Completion
    Apr 2012
    Completion
    Jul 2012
    NCT00920582
  • Phase 3
    Completed

    Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer

    Margetuximab, Trastuzumab

    HER-2 Positive Breast Cancer, Metastatic Neoplasm

    Enrollment
    624
    Start
    Aug 2015
    Primary Completion
    Aug 2021
    Completion
    Jun 2022
    NCT02492711
  • Phase 2/3
    Completed

    The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus

    Teplizumab, Placebo

    Type 1 Diabetes Mellitus

    Enrollment
    554
    Start
    Oct 2006
    Primary Completion
    Jun 2010
    Completion
    Aug 2011
    NCT00385697
  • Phase 2/3
    Completed

    Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

    margetuximab, Retifanlimab

    Gastric Cancer, Gastroesophageal Junction Cancer +1

    Enrollment
    82
    Start
    Sep 2019
    Primary Completion
    Jan 2024
    Completion
    Mar 2025
    NCT04082364
  • Phase 2/3
    Withdrawn

    Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck

    enoblituzumab, MGA012

    Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck

    Enrollment
    0
    Start
    Oct 2019est.
    Primary Completion
    Oct 2020est.
    Completion
    Oct 2022est.
    NCT04129320
  • Phase 2
    Terminated

    Monoclonal Antibody RAV12 and Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

    RAV12, Gemcitabine

    Pancreatic Cancer

    Enrollment
    2
    Start
    Apr 2008
    Primary Completion
    Jan 2009
    Completion
    Mar 2009
    NCT00625586
  • Phase 2
    Terminated

    Treatment of West Nile Virus With MGAWN1

    MGAWN1, Placebo - normal saline

    West Nile Neuroinvasive Disease, West Nile Virus Infection +4

    Enrollment
    13
    Start
    May 2009
    Primary Completion
    Feb 2011
    Completion
    May 2011
    NCT00927953
  • Phase 2
    Completed

    Phase 2 Study of the Monoclonal Antibody MGAH22 (Margetuximab) in Patients With Relapsed or Refractory Advanced Breast Cancer

    Margetuximab

    Breast Cancer

    Enrollment
    25
    Start
    Mar 2013
    Primary Completion
    Dec 2016
    Completion
    Apr 2017
    NCT01828021
  • Phase 2
    Terminated

    Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

    Enoblituzumab, Retifanlimab

    Head and Neck Cancer, Head and Neck Neoplasms +1

    Enrollment
    62
    Start
    Mar 2021
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT04634825
  • Phase 2
    Terminated

    A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

    vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B)

    Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer +15

    Enrollment
    192
    Start
    Jun 2023
    Primary Completion
    Jul 2024
    Completion
    Jan 2025
    NCT05551117
  • Phase 2
    Completed

    A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

    lorigerlimab, docetaxel

    Androgen-Independent Prostatic Cancer, Androgen-Independent Prostatic Neoplasms +7

    Enrollment
    154
    Start
    Sep 2023
    Primary Completion
    Feb 2026
    Completion
    Mar 2026
    NCT05848011
  • Phase 2
    Recruiting

    A Study of Lorigerlimab in Participants With Advanced Solid Tumors

    Lorigerlimab

    Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma +9

    Enrollment
    80
    Start
    May 2025
    Primary Completion
    Jul 2027est.READOUT
    Completion
    Dec 2027est.
    NCT06730347
  • Phase 1/2
    Terminated

    Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis

    teplizumab

    Psoriasis

    Enrollment
    1
    Start
    Dec 2009
    Primary Completion
    Jul 2010
    Completion
    Jul 2010
    NCT00954915
  • Phase 1/2
    Terminated

    Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

    Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off, Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off

    AML

    Enrollment
    244
    Start
    Jun 2014
    Primary Completion
    Jul 2022
    Completion
    Jul 2022
    NCT02152956
  • Phase 1/2
    Completed

    Combination Margetuximab and Pembrolizumab for Advanced, Metastatic HER2(+) Gastric or Gastroesophageal Junction Cancer

    Margetuximab 10 mg/kg, Margetuximab 15 mg

    Gastric Cancer, Stomach Cancer +1

    Enrollment
    95
    Start
    Jan 2016
    Primary Completion
    Jan 2021
    Completion
    Jan 2021
    NCT02689284
  • Phase 1/2
    Completed

    MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer

    MGD007 + MGA012

    Colorectal Cancer Metastatic

    Enrollment
    38
    Start
    Jun 2018
    Primary Completion
    Feb 2020
    Completion
    Feb 2020
    NCT03531632
  • Phase 1/2
    Terminated

    MGC018 With or Without MGA012 in Advanced Solid Tumors

    vobramitamab duocarmazine

    Squamous Cell Carcinoma of Head and Neck, Triple Negative Breast Cancer +4

    Enrollment
    143
    Start
    Nov 2018
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT03729596
  • Phase 1
    Completed

    RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

    monoclonal antibody RAV12

    Cancer

    Enrollment
    53
    Start
    Dec 2004
    Primary Completion
    May 2008
    Completion
    May 2008
    NCT00101972
  • Phase 1
    Completed

    A Trial to Evaluate the Safety of a Single Intravenous Infusion of MGAWN1 in Healthy Adults

    MGAWN1, MGAWN1

    West Nile Virus

    Enrollment
    40
    Start
    Aug 2007
    Primary Completion
    Dec 2008
    Completion
    Jan 2009
    NCT00515385
  • Phase 1
    Completed

    Safety Study of MGAH22 in HER2-positive Carcinomas

    margetuximab

    Breast Cancer, Gastric Cancer

    Enrollment
    66
    Start
    Jul 2010
    Primary Completion
    Jun 2022
    Completion
    Jun 2022
    NCT01148849
  • Phase 1
    Terminated

    Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes

    teplizumab or placebo

    Type 1 Diabetes Mellitus

    Enrollment
    1
    Start
    Aug 2010
    Primary Completion
    Feb 2011
    Completion
    Feb 2011
    NCT01189422
  • Phase 1
    Completed

    Safety Study of MGA271 in Refractory Cancer

    MGA271

    Prostate Cancer, Melanoma +5

    Enrollment
    179
    Start
    Jul 2011
    Primary Completion
    Apr 2019
    Completion
    Apr 2019
    NCT01391143
  • Phase 1
    Terminated

    Tissue Procurement Substudy for Participants in Study CP-MGA271-01

    MGA271

    Melanoma

    Enrollment
    6
    Start
    Jul 2013
    Primary Completion
    Oct 2016
    Completion
    Oct 2016
    NCT01918930
  • Phase 1
    Completed

    Phase 1 Study of MGD007 in Relapsed/Refractory Metastatic Colorectal Carcinoma

    MGD007

    Colorectal Carcinoma

    Enrollment
    95
    Start
    Oct 2014
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT02248805
  • Phase 1
    Completed

    Phase 1 Study of MGD010 in Healthy Subjects

    MGD010, Placebo

    Healthy Subjects

    Enrollment
    73
    Start
    Feb 2015
    Primary Completion
    Feb 2017
    Completion
    Feb 2017
    NCT02376036

1-25 of 42

Search ClinicalTrials.gov for “Macrogenics”